# US 2018/0022821 A1 · Compositions and methods for tumor transduction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022821 A1
- Document ID: US20180022821A1
- Status: Published application
- Kind: A1
- Application number: 15/670,535
- Filed: 2017-08-07
- Published: 2018-01-25
- Earliest claimed: 2015-10-30
- Assignees: Aleta Biotherapeutics Inc.
- Applicants: Aleta Biotherapeutics Inc.
- Inventors: Roy Lobb; Paul Rennert
- Web page: https://patentgrep.com/patent/US20180022821A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61K 40/4254: {Adhesion molecules, e.g. NRCAM, EpCAM or cadherins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61K 47/6839: {the antibody targeting material from viruses}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- C12N 5/0636: {T lymphocytes}
- C12N 15/86: Viral vectors
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2239/13: Antibody-based
- A61K 2239/31: characterized by the route of administration
- A61K 2239/49: Breast
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 2510/00: Genetically modified cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.

## Claims

### Claim at position 1

1-32. (canceled)

### Claim 33

An adenoviral vector, comprising a nucleotide sequence encoding a fusion protein comprising (a) an antibody, or antigen-binding fragment thereof, that binds a tumor antigen; and (b) a polypeptide target for a cellular therapeutic, antibody, or antibody-drug conjugate.

### Claim 34 (depends on 33)

The vector of claim 33, wherein the polypeptide target is a B cell antigen.

### Claim 35 (depends on 34)

The vector of claim 34, wherein the B cell antigen is CD19 or CD22.

### Claim 36 (depends on 33)

The vector of claim 33, wherein the tumor antigen is HER-2/neu, c-met, EGFR, Ga733\EpCAM, CD20, ROR1, or BCMA.

### Claim 37 (depends on 33)

The vector of claim 33, wherein the antigen-binding fragment is an Fab, scFv, Fv, or VHH.

### Claim 38 (depends on 33)

The vector of claim 33, wherein the cellular therapeutic is a CAR-T cell or CAR-NK cell.

### Claim 39 (depends on 33)

A method of treating a subject having a tumor, comprising administering to the subject the adenoviral vector of claim 33.

### Claim 40

An oncolytic viral vector, comprising a nucleotide sequence encoding a fusion protein comprising (a) an antibody, or antigen-binding fragment thereof, that binds a tumor antigen; and (b) a polypeptide target for a cellular therapeutic, antibody, or antibody-drug conjugate.

### Claim 41 (depends on 40)

The vector of claim 40, wherein the polypeptide target is a B cell antigen.

### Claim 42 (depends on 41)

The vector of claim 41, wherein the B cell antigen is CD19 or CD22.

### Claim 43 (depends on 40)

The vector of claim 40, wherein the tumor antigen is HER-2/neu, c-met, EGFR, Ga733\EpCAM, CD20, ROR1, or BCMA.

### Claim 44 (depends on 40)

The vector of claim 40, wherein the antigen-binding fragment is an Fab, scFv, Fv, or VHH.

### Claim 45 (depends on 40)

The vector of claim 40, wherein the cellular therapeutic is a CAR-T cell or CAR-NK cell.

### Claim 46 (depends on 40)

The vector of claim 40, wherein the oncolytic viral vector is an autonomous parvoviral vector, myxoma viral vector, paramyxoviral vector, reoviral vector, picornaviral vector, vaccinia viral vector, adenoviral vector, herpes simplex viral vector, or a vesicular stomatitis viral vector.

### Claim 47

A method of treating a subject having a tumor, comprising administering to the subject an oncolytic viral vector comprising a nucleotide sequence encoding a fusion protein comprising (a) an antibody, or antigen-binding fragment thereof, that binds a tumor antigen; and (b) a polypeptide target for a cellular therapeutic, antibody, or antibody-drug conjugate.

### Claim 48 (depends on 47)

The method of claim 47, wherein the polypeptide target is a B cell antigen.

### Claim 49 (depends on 48)

The method of claim 48, wherein the B cell antigen is CD19 or CD22.

### Claim 50 (depends on 47)

The method of claim 47, wherein the tumor antigen is HER-2/neu, c-met, EGFR, Ga733\EpCAM, CD20, ROR1, or BCMA.

### Claim 51 (depends on 47)

The method of claim 47, wherein the antigen-binding fragment is an Fab, scFv, Fv, or VHH.

### Claim 52 (depends on 47)

The method of claim 47, wherein the oncolytic viral vector transforms a tumor cell in the subject.

### Claim 53 (depends on 52)

The method of claim 52, wherein the transformed tumor cell secretes the fusion protein.

### Claim 54 (depends on 53)

The method of claim 53, wherein the fusion protein binds a tumor antigen on the transformed tumor cell.

### Claim 55 (depends on 53)

The method of claim 53, wherein the fusion protein binds a tumor antigen on a non-transformed tumor cell.

### Claim 56 (depends on 47)

The method of claim 47, wherein the cellular therapeutic is a CAR-T cell or CAR-NK cell.

### Claim 57 (depends on 56)

The method of claim 56, further comprising administering the cellular therapeutic to the subject.

### Claim 58 (depends on 57)

The method of claim 57, wherein upon administration, the cellular therapeutic binds to the fusion protein.

### Claim 59 (depends on 58)

The method of claim 58, wherein binding of the cellular therapeutic to the fusion protein induces killing of the tumor.

### Claim 60 (depends on 47)

The method of claim 47, wherein the oncolytic viral vector is an autonomous parvoviral vector, myxoma viral vector, paramyxoviral vector, reoviral vector, picornaviral vector, vaccinia viral vector, adenoviral vector, herpes simplex viral vector, or a vesicular stomatitis viral vector.
